Dr. Reddy's Laboratories: Multiple Drug Launches To Drive Significant Growth

Jul. 31, 2022 1:13 AM ETDr. Reddy's Laboratories Limited (RDY)
Mayank N. Sharma profile picture
Mayank N. Sharma


  • Dr. Reddy's has launched multiple drugs in the US market recently which are expected to drive significant growth.
  • The launch of bortezomib drug to give the company access to $1.2 billion myeloma treatment market.
  • I assign a Hold rating for RDY after taking into consideration all the growth and risk factors.

Manufacture process of vaccine,production of Covid-19 vaccine. Bio science


Investment Thesis

Dr. Reddy's Laboratories Limited (NYSE:RDY) is an Indian multinational pharmaceutical company headquartered in Hyderabad, India. In this thesis, I will primarily be analyzing multiple drug launches by the company in the US market. I will also analyze the risk

Quant Ratings

Seeking Alpha

This article was written by

Mayank N. Sharma profile picture
I am an Equity Research Analyst. I have a passion in researching undervalued companies with high growth potential. Having 4 years of fundamental analysis experience at hand, I look forward to keep investors informed about the lucrative investment opportunities in the Equity market.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.